We therefore identified ki67lowBCL2high phenotype as an aberrant blast profile in both CD34+ and CD34− AMLs and MDS-RAEB but not at the pre-leukemic stage of MDS-noEB. This evidence concerns the gene CD34 and myelodysplastic syndrome with excess blasts.